【舒泰神:子公司STSP-0601获美国FDA临床试验许可】舒泰神公告,公司子公司贝捷泰近日收到美国FDA正式函件,同意STSP-0601关于治疗伴抑制物血友病A或B患者出血开展临床试验。该药品此前已于2026年06月获国家药监局核准签发《药品注册证书》。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.